OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

WellQuest Medical & Wellness Corporation ("the Company"). See Item 1 in our filing on August 14, 2015 for the three and six months ended June 30, 2015 for discussion of the Company's subsidiaries.

2) Address of the issuer's principal executive offices

Company Headquarters
Address 1: 3400 SE Macy Rd.
Address 2: Suite 18
Address 3: Bentonville, AR 72712
Phone: (479) 845-4476
Email: rbridges@wellquestmedical.com
Website(s): www.wellquestmedical.com

IR Contact
Name: Josh Estes, CFO
Address 1: 3400 SE Macy Rd.
Address 2: Suite 18
Address 3: Bentonville, AR 72712
Phone: (479) 845-4476
Email: jestes@wellquestmedical.com

3) Security Information

Trading Symbol: WEQL
Exact title and class of securities outstanding: Common Stock
CUSIP: 94973Q
Par or Stated Value: $0.001
Total shares authorized: 150,000,000 as of: June 30, 2015
Total shares outstanding: 35,776,951 as of: June 30, 2015

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: Series A Preferred Stock
CUSIP: N/A
Par or Stated Value: $0.01
Total shares authorized: 75,000 as of: June 30, 2015
Total shares outstanding: 25,515 as of: June 30, 2015

Transfer Agent
Name: Continental Stock Transfer & Trust Company
Address 1: 17 Battery Place
Address 2: New York, NY 10004
Phone: (212) 509-4000
Is the Transfer Agent registered under the Exchange Act?* Yes: X No:

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.
List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

Issuance of common stock:

On November 13, 2013, the debentures issued during September and October 2013 to members of the Company's board of directors were converted to 1,448,649 shares of common stock. The conversion price was $0.02775 per share.

There are no restrictions on the common stock issued on November 13, 2013.

During 2014, the Company issued to two members of the Company's board of directors convertible debentures totaling $28,000. These funds are to be used for operations. Interest incurred on the debentures is 10% and the debentures matured December 31, 2014. In accordance with the debenture agreements, the debentures are convertible to common stock at the option of the holder at any time after the date of issuance. The conversion rate is based on the last sale price of the Company's common stock on the date of conversion. On July 1, 2014, the debenture holders converted $21,500 to 1,194,445 shares of common stock in accordance with the debenture agreements. As of June 30, 2015, the balance on these debentures was $6,500.

There are no restrictions on the common stock issued on July 1, 2014.

During 2014, WellQuest issued to a member of the Board of Directors a convertible debenture for $60,000. These funds are to be used for operations. Interest incurred on the debenture is 10% and the debenture mature December 31, 2015. In accordance with the debenture agreement, the debenture is convertible to common stock at the option of the holder at any time after the date of issuance. The conversion rate shall be $0.08888.

Issuance of stock options:

On August 4, 2008, the Company granted stock options for 500,000 shares of stock at an exercise price of $0.08888 per share. The options are fully vested, have a termination date of August 3, 2018 and the Company has reserved 500,000 shares of common stock for the exercise of these options.

On December 14, 2009, the Company granted stock options for 3,852,250 shares of stock at exercise prices ranging from $0.032 to $0.0352 per share. During 2014, 98,533 options were exercised for $3,468.

On December 21, 2010, the Company granted stock options for 1,350,000 shares of stock at exercise prices ranging from $0.015 to $0.0165 per share. During 2014, 450,000 options were exercised for $7,425.

On January 23, 2012, the Company granted stock options for 2,400,000 shares of stock at an exercise price of $0.008 per share, which represented the fair value of those shares on the grant date. The options are subject to a vesting schedule

as follows: 800,000 options on January 23, 2013; 800,000 options on January 23, 2014; and 800,000 options on January 23, 2015. The options have a termination date of January 23, 2017. Compensation expense was calculated at $19,200, which will be recognized over the vesting period. 500,000 options awarded under this grant have been forfeited. The amount expensed in the six months ended June 30, 2015 related to these options was $444. During 2014, 466,666 options were exercised for $4,107. The Company has reserved 1,433,334 shares of common stock for the exercise of these options.

On January 14, 2013, the Company granted stock options for 50,000 shares of stock at an exercise price of $0.03 per share. The options are subject to a vesting schedule as follows: 16,667 options on January 14, 2014; 16,667 options on January 14, 2015; and 16,667 options on January 14, 2016. The options have a termination date of January 14, 2018. Compensation expense was calculated at $1,500, which will be recognized over the vesting period. 25,000 options awarded under this grant have been forfeited. The Black-Scholes calculation used to value these options included a risk-free interest rate of 0.78%, an estimated volatility of 510%, no dividend yield and no forfeiture rate and an expected life of five years. The amount expensed in the six months ended June 30, 2015 related to these options was $175. Remaining compensation expense is $125 and will be recognized in 2015. The Company has reserved 25,000 shares of common stock for the exercise of these options.

On May 8, 2013, the Company granted stock options for 100,000 shares of stock at an exercise price of $0.026 per share. The options are subject to a vesting schedule as follows: 33,333 options on May 8, 2014; 33,333 options on May 8, 2015; and 33,334 options on May 8, 2016. The options have a termination date of May 8, 2018. Compensation expense was calculated at $2,500, which will be recognized over the vesting period. The Black-Scholes calculation used to value these options included a risk-free interest rate of 0.75%, an estimated volatility of 491%, no dividend yield and no forfeiture rate and an expected life of five years. The amount expensed in the six months ended June 30, 2015 related to these options was a $417. Remaining compensation expense is approximately $700 and will be recognized in 2015 and 2016. The Company has reserved 100,000 shares of common stock for the exercise of these options.

On May 14, 2014, The Company granted stock options for 1,175,000 shares of stock at an exercise price of $0.056 per share. The options are subject to a vesting schedule as follows: 800,000 options on May 14, 2014; 121,667 options on May 14, 2015; 121,667 options on May 14, 2016 and 121,667 options on May 14, 2017. The options have a termination date of May 14, 2024. Compensation expense was calculated at $65,240, of which $44,800 was recognized immediately and the remaining $20,440 will be recognized over the vesting period. The Black-Scholes calculation used to value these options included a risk-free interest rate of 1.57%, an estimated volatility of 672%, no dividend yield and no forfeiture rate and an expected life of five years. The amount expensed in the six months ended June 30, 2015 related to these options was a $3,500. Remaining compensation expense is approximately $13,000 and will be recognized in 2015 through 2017. The Company has reserved 1,175,000 shares of common stock for the exercise of these options.

On February 18, 2015, The Company granted stock options for 750,000 shares of stock at an exercise price of $0.028 per share. The options are subject to a vesting schedule as follows: 500,000 options on February 18, 2015; 83,333 options on February 18, 2016; 83,333 options on February 18, 2017 and 83,334 options on February 18, 2018. The options have a termination date of February 18, 2025. Compensation expense was calculated at $21,000, of which $14,000 was recognized immediately and the remaining $7,000 will be recognized over the vesting period. The Black-Scholes calculation used to value these options included a risk-free interest rate of 2.07%, an estimated volatility of 632%, no dividend yield and no forfeiture rate and an expected life of ten years. The amount expensed in the six months ended June 30, 2015 related to these options was a $14,972. Remaining compensation expense is approximately $6,000 and will be recognized in 2015 through 2018. The Company has reserved 750,000 shares of common stock for the exercise of these options.

There are no restrictions on the common stock issued through the exercise of stock options during 2014.

5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

A. Balance sheet;
B. Statement of income;
C. Statement of cash flows;
D. Financial notes; and
E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otciq.com in the field below.

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

The Company's financial statements and financial notes for the three and six months ended June 30, 2015 are incorporated by reference. See Item 3 in our filing on August 14, 2015 for the three and six months ended June 30, 2015.

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

A. a description of the issuer's business operations;

See "Notes to Consolidated Financial Statements" included in Item 3 in our filing on August 14, 2015 for the three and six months ended June 30, 2015.

B. Date and State (or Jurisdiction) of Incorporation:

See Item 1 in our filing on August 14, 2015 for the three and six months ended June 30, 2015.

C. the issuer's primary and secondary SIC Codes;

8011

D. the issuer's fiscal year end date;

December 31

E. principal products or services, and their markets;

See "Notes to Consolidated Financial Statements" included in Item 3 in our filing on August 14, 2015 for the three and six months ended June 30, 2015.

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company maintains our principal office at 3400 SE Macy Rd., #18, Bentonville, Arkansas 72712. Our current office space is leased with a base cost of $15,256 per month and runs through September 2015 with options for additional lease terms. The space consists of approximately 6,956 square feet. Additionally, we lease an additional two spaces totaling 2,900 square feet at a cost of $3,400 per month for administrative and billing services which were previously housed in the medical clinic service space. The leases for these spaces run through August and September 2015. Our office space in Tulsa, Oklahoma is owned by us. The space consists of approximately 10,414 square feet. Should we need additional space in Northwest Arkansas or Tulsa due to the continued growth of the medical services, we do not anticipate any difficulty securing alternative or additional space on terms acceptable to us. During 2012, the Company purchased a parcel of land in Tulsa, Oklahoma for approximately $792,000. Construction of the Company's second location in Tulsa was completed in November 2013 with the facility opening on November 11, 2013.

On May 1, 2015, the Company renewed the lease for the Bentonville facility. The lease will commence on September 1, 2015 and expire on September 30, 2021. From September 1, 2015 through September 30, 2018, the monthly lease payment will be $13,968 per month and from October 1, 2018 through September 30, 2021, the monthly lease payment will be $15,365 per month.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Names:	Titles:
Steve Swift	President, CEO and Director
Josh Estes	Chief Financial Officer
Curtis Rice	Vice President and Director
John O'Connor	Secretary and Director
Robert J. Zasa	Director
Regent Private Capital, LLC	Control Person

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

   None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

   None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

   None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

   None

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Names:	Contact:	Address:	Percentage Ownership:
Steve Swift	N/A	3400 SE Macy Rd., Ste. 18 Bentonville, AR 72712	43.47%
Curtis Rice	N/A	3400 SE Macy Rd., Ste. 18 Bentonville, AR 72712	12.08%

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel
Name: John O'Connor
Firm: Newton, O'Connor, Turner & Ketchum, PC
Address 1: 2700 Bank of America Center
Address 2: 15 W. Sixth St.
Address 3: Tulsa, OK 74119
Phone: (918) 587-0101
Email: joconnor@newtonoconnor.com

Accountant or Auditor

Name: Todd Wisdom
Firm: HoganTaylor LLP
Address 1: 688 E. Millsap Rd.
Address 2: Suite 203
Address 3: Fayetteville, AR 72703
Phone: (479) 521-9191
Email: twisdom@hogantaylor.com

Investor Relations Consultant
N/A

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.
N/A

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Steve Swift, President and Chief Executive Officer, certify that:

1. I have reviewed this quarterly disclosure statement of WellQuest Medical & Wellness Corporation;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 14, 2015

/s/ Steve Swift

I, Josh Estes, Chief Financial Officer, certify that:

1. I have reviewed this quarterly disclosure statement of WellQuest Medical & Wellness Corporation;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 14, 2015

/s/ Josh Estes